{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"description":"Objective response defined as a best overall response of complete response (CR) or partial response (PR) based on the CR and requires all of the following:\n\n* Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days.\n* \\<5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed.\n* No increase in size or number of lytic bone lesions.\n* Disappearance of soft tissue plasmacytomas.\n\nPR requires all of the following:\n\n* ≥50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days.\n* Reduction in 24-hour urinary light chain extraction by ≥90% or to \\<200 mg, maintained at least 42 days.\n* For patients with non-secretory myeloma, ≥50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days.","groups":[{"description":"Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity\n\npomalidomide: Oral pomalidomide 4 mg on Days 1-21 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity","id":"OG000","title":"Pomalidomide"}],"paramType":"NUMBER","populationDescription":"Intent to treat population includes all participants enrolled.","reportingStatus":"POSTED","timeFrame":"From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.","title":"Percentage of Participants With Objective Response According to European Group for Blood and Marrow Transplantation (EBMT) Criteria Based on Investigator Assessment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}